Emerging drugs for hyperlipidemia

Expert Opinion on Emerging Drugs

Volumn 15, Issue 3, 2010, Pages 433-451

  Paras, Christos ^a   Hussain, M Mahmood ^b   Rosenson, Robert S ^a,c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Anacetrapib; Apolipoprotein B; Cholesterol ester transfer protein; Dalctetrapib; HDL cholesterol; LDL cholesterol; Lomitapide; Microsomal transfer protein inhibitor; Secretory phospholipase A2

Indexed keywords

AEGR 733; ALEGLITAZAR; ANACETRAPIB; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BILE ACID SEQUESTRANT; BMS 201308; CLOFIBRATE; COLESEVELAM; COLESTYRAMINE; CP 346086; DALCETRAPIB; DIGOXIN; EPROTIROME; EZETEMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GFT 505; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; LAROPIPRANT; LOMITAPIDE; MEVINOLIN; MIPOMERSEN; MURAGLITIZAR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVISTATIN; SUCCINOBUCOL; TESAGLITAZAR; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; BILE DUCT CARCINOMA; BLOATING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; FLUSHING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ABSORPTION; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MUSCLE CRAMP; MUSCLE DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARESTHESIA; PROTEIN MODIFICATION; PRURITUS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; RISK FACTORS;

EID: 77955877432     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.481282     Document Type: Review

References (98)

1. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S
2. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837
3. American Heart Association Statistical Fact Sheet-Risk Factors; 2009 update
4. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER study group). N Engl J Med 2008;359:2195-2207
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Study Prevention Group). N Engl J Med 1995;333:1301-1307
6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandanavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTT-LLA). Lancet 2003;361:1149-1158 (Pubitemid 36398384)
7. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143
8. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46
9. Shih PT, Elices MJ, Fang ZT, et al. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating 1 integrin. J Clin Invest 1999;103:613
10. Rosenson RS, Hislop C, McConnell D, et al. Effects of a selective inhibitor of secretory phospholipase A2 on low density lipoproteins and inflammatory pathways. Lancet 2009;373:649-658
11. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001;86:386
12. Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 2002;161:433
13. Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 1999;146:161
14. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996;94:713
15. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376
16. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesterol ester transfer protein: a novel for raising HDL and inhibiting atherosclerosis. Atheroscler Thromb Vasc Biol 2003;23:160-167
17. Barter P, Gotto AM, LaRossa JC, et al.; for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310
18. Kearney PM, Blackwell PM, Collins R, et al.; for CTT. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125
19. Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(Suppl):1K-34K
20. Fruchart JC, Brewer HB Jr, Leitersdorf E, et al. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate consensus group. Am J Cardiol 1998;81(7):912-917
21. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-2093
22. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the committee of Principal Investigators. Lancet 1984;2(8403):600-604
23. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease- a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154(5):943-953
24. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151(9):1873-1874
25. Miller DB, Spence JD. Clinical pharmacokinetics of fibric derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-162
26. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264(1):71-75
27. Grundy SM, Mok HY, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22(1):24-36
28. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994;154(14):1586-1595
29. Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 1994;154:1557
30. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA 1990;264(6):723-726
31. Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009;361:2180-2183
32. Taylor AJ, Todd CV, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122
33. Wetterau JR, Zilversmit DB. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J Biol Chem 1984;259:10863-10866
34. Wetterau JR, Combs KA, Spinner SN, et al. Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J Biol Chem 1990;265:9800-9807
35. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001
36. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Ann Rev Nutr 2000;20:663-697
37. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003;44:22-32
38. Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008;19:572-578
39. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-754
40. Miyazaki T, Miwa S, Kodama H, et al. Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (MTP) inhibitor. J Toxicol Sci 2007;32:161-177
41. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-1901
42. Ueshima K, kihisa-Umeno H, Nagayoshi A, et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005;28:247-252
43. Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46:872-884
44. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50:S172-7
45. Rosenson RR, Hislop C, Elliot M, et al. Abstract 1928: effect of a selective inhibitor of secretory phospholipase A2 on low density and very low density lipoprotein subclasses in stable coronary heart disease patients-PLASMA 2 trial. Circulation 2008;118:S-406-7
46. Shinomiya M, Shirai K, Saito Y, et al. Inhibition of intimal thickening of the carotid artery of rabbits and of outgrowth of explants of aorta by probucol. Atherosclerosis 1992;97:143-148
47. Ishizaka N, Kurokawa K, Taguchi J, et al. Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1995;118:53-56
48. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-372 (Pubitemid 27328366)
49. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855-862
50. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-616
51. Tardif J, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-558
52. Otvos JD, Collin D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-1563
53. Pitt B, Mancini GB, Rosman HS, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26(5):1133-1139
54. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31(4):811-822
55. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2006;295:2581-2586
56. AstraZeneca discontinues development of GALIDA (Tesaglitazar). Astrazeneca 2006-05-104
57. Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981;22:323-338
58. Morkin E, Ladenson P, Goldman S, et al. Thyroid hormone analogues for the treatment of hypercholesterolemia and heart failure: past, present, and future prospects. J Mol Cell Cardiol 2004;37:1137-1146
59. Salter AM, Hayashi R, Al-Seeni M, et al. Effects of hypothyroidism and high-fat feeding on mRNA concentrations for the low-density lipoprotein receptor and on acyl-CoA: cholesterol acyltransferase activities in rat liver. Biochem J 1991;276:825-832
60. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-156
61. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497-505
62. Sorbera LA, Martin L, Silvestre J, et al. Implitapide. Drugs Fut 2000;25:1138-1144
63. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-1901
64. Barter PJ, Nicholls S, Rye KA, et al.; for the ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22[s5]
65. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620
66. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515
67. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304
68. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506
69. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose response study. Circulation 2002;105:2159-2165
70. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-1088
71. Stein EA, Stroes ESG, Steiner G, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from 5 phase II clinical trials. Am J Cardiol 2009;104(1):82-91
72. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907
73. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352
74. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994;90:1935
75. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292
76. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729
77. Visser ME, Akdim F, Tribble DL, et al. Effect of ApoB synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. In press
78. Raal EF, Santos RD, Blom DJ, et al. Mipomersen an apolipoprotein B synthesis inhibitor for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
79. Press release Genzyme February 2010
80. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675
81. Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009;53:60-65
82. Shaposhnik Z, Wang X, Trias J, et al. The synergistic inhibition of atherogenesis in ApoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2008;50:623-629
83. Maccubin D, Koren M, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
84. Maccubin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/ laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia. Int J Clin Practice 2008;62(12):1959-1970
85. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156
86. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37(2):161-165
87. Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-1273
88. Kotowski IK, Pertsemlidis A, Luke R, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Human Genet 2006;78:410-422
89. Tardif JC, Gregoire J, Schwartz L, et al.; for the Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-558
90. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-422
91. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Artrerioscler Thromb Vasc Biol 2006;26:1094-1100
92. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/ gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374(9684):96-98
93. Press release Genfit November 23, 2009
94. Tardif JC, Gregoire J, L'Allier PL, et al. for the Canadian Antioxidant Restenosis Trial (CART-2) Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008;197:480-486
95. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, doubleblind, placebo-controlled trial. Lancet 2008;371:1761-1768
96. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-916
97. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245
98. Scandinavian Simvistatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvistatin Survival Study (4S). Lancet 1994;344(8934):1383-1389